Figure 4From: Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II studyDisease-free survival rates by clinical T stage (panels a), ypT stage (panels b), tumor regression (panels c) and prognostic score (panels d). TRG: tumor regression grade.Back to article page